These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 11713766

  • 21. E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin.
    Dong YB, Yang HL, McMasters KM.
    Cancer Gene Ther; 2003 Mar; 10(3):168-78. PubMed ID: 12637937
    [Abstract] [Full Text] [Related]

  • 22. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus.
    Anderson SC, Johnson DE, Harris MP, Engler H, Hancock W, Huang WM, Wills KN, Gregory RJ, Sutjipto S, Wen SF, Lofgren S, Shepard HM, Maneval DC.
    Clin Cancer Res; 1998 Jul; 4(7):1649-59. PubMed ID: 9676839
    [Abstract] [Full Text] [Related]

  • 23. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
    Idogawa M, Sasaki Y, Suzuki H, Mita H, Imai K, Shinomura Y, Tokino T.
    Clin Cancer Res; 2009 Jun 01; 15(11):3725-32. PubMed ID: 19458054
    [Abstract] [Full Text] [Related]

  • 24. All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma.
    Nakashima T, Sun SY, Lotan R, Fujiwara T, Yasumatsu R, Komiyama S, Clayman GL.
    Laryngoscope; 2001 Aug 01; 111(8):1459-64. PubMed ID: 11568584
    [Abstract] [Full Text] [Related]

  • 25. Clinical trails referral resource. Clinical trials of adenovirus-p53 gene therapy.
    Zwiebel JA, Nagler C, Smiley JK, Cheson BD.
    Oncology (Williston Park); 1998 Aug 01; 12(8):1172, 1175. PubMed ID: 11236309
    [No Abstract] [Full Text] [Related]

  • 26. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer.
    Spitz FR, Nguyen D, Skibber JM, Cusack J, Roth JA, Cristiano RJ.
    Anticancer Res; 1996 Aug 01; 16(6B):3415-22. PubMed ID: 9042200
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
    Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL.
    Cancer Chemother Pharmacol; 1999 Aug 01; 44(2):143-51. PubMed ID: 10412949
    [Abstract] [Full Text] [Related]

  • 29. p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate.
    Kunisaki R, Ikawa S, Maeda T, Nakazaki Y, Kurita R, Harata M, Shutoh Y, Bai YS, Soda Y, Tanabe T, Dohi T, Kato R, Ikawa Y, Asano S, Tani K.
    J Gene Med; 2006 Sep 01; 8(9):1121-30. PubMed ID: 16832836
    [Abstract] [Full Text] [Related]

  • 30. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers.
    Clayman GL, Frank DK, Bruso PA, Goepfert H.
    Clin Cancer Res; 1999 Jul 01; 5(7):1715-22. PubMed ID: 10430074
    [Abstract] [Full Text] [Related]

  • 31. [Therapeutic effect of adenovirus-mediated transfer of the wild-type p53 gene with cisplatin].
    Fujiwara T, Ogawa N, Kagawa S, Nishizaki M, Yasuda T, Tanaka N, Orita K, Roth JA.
    Gan To Kagaku Ryoho; 1996 Jul 01; 23(8):1085-8. PubMed ID: 8687228
    [No Abstract] [Full Text] [Related]

  • 32. Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis.
    Gu J, Zhang L, Swisher SG, Liu J, Roth JA, Fang B.
    Oncogene; 2004 Feb 12; 23(6):1300-7. PubMed ID: 14676844
    [Abstract] [Full Text] [Related]

  • 33. p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer.
    Bookstein R, Demers W, Gregory R, Maneval D, Park J, Wills K.
    Semin Oncol; 1996 Feb 12; 23(1):66-77. PubMed ID: 8607033
    [Abstract] [Full Text] [Related]

  • 34. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
    Mujoo K, Maneval DC, Anderson SC, Gutterman JU.
    Oncogene; 1996 Apr 18; 12(8):1617-23. PubMed ID: 8622881
    [Abstract] [Full Text] [Related]

  • 35. [Molecular therapy for human cancer with tumor suppressor p53 gene transfer].
    Fujiwara T, Inoue F, Tanaka N.
    Gan To Kagaku Ryoho; 1998 Jan 18; 25(2):194-200. PubMed ID: 9474928
    [Abstract] [Full Text] [Related]

  • 36. Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers.
    Jiang GL, Huang S.
    Cancer Res; 2001 Mar 01; 61(5):1796-8. PubMed ID: 11280725
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
    Nielsen LL, Gurnani M, Syed J, Dell J, Hartman B, Cartwright M, Johnson RC.
    Hum Gene Ther; 1998 Mar 20; 9(5):681-94. PubMed ID: 9551616
    [Abstract] [Full Text] [Related]

  • 39. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck.
    Frank DK, Frederick MJ, Liu TJ, Clayman GL.
    Clin Cancer Res; 1998 Oct 20; 4(10):2521-8. PubMed ID: 9796986
    [Abstract] [Full Text] [Related]

  • 40. Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model.
    Zhu DE, Höti N, Song Z, Jin L, Wu Z, Wu Q, Wu M.
    Cancer Gene Ther; 2006 Aug 20; 13(8):762-70. PubMed ID: 16543917
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.